A Phase 2 interventional study of MDMA assisted psychotherapy and Psychotherapy in Post Traumatic Stress Disorder, sponsored by Remedy. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Remedy · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada — 34 open to participants now, 42 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 48th largest by planned enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 22 of the 41 other live ones, and was the 101st registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →34 of the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–65
COMPASS Pathways · Sites in Canada, United States
Ages 18+
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 19+ · Women only
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 22 · Phase 3 8 · Phase 4 2
First in 2007; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 54 across the 113 interventional studies, 303 across the 14 observational. Of the 65 that completed or were terminated, 6 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 127 have an industry lead sponsor. The 10 most frequent:
Remedy is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Remedy has 2 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Stress Disorders, Post-Traumatic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT07309302Université du Québec a MontréalPsychosocial Factors and Efficacy of Remote Cognitive Remediation for Post-Traumatic Stress Disorder | 2026-12 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT06044675RemedyMDMA-Assisted CBCT for PTSD vs CBCT RCT | 2027-03-31 |
| NCT06335043London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPersonalized Pharmacotherapy Using Pharmacogenetics in Veterans | 2027-04-25 |
Add all 7 to your calendar (.ics) → With an account.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly impacts interpersonal relationships and the functioning of individuals and their loved ones. There is also a well-established reciprocal relationship between interpersonal relationships, PTSD, and recovery.
CBCT is a manualized treatment for PTSD that simultaneously addresses PTSD symptoms and relationship satisfaction. It provides dyads with behavioral tools to navigate PTSD-related challenges, as well as the knowledge behind PTSD and how it impacts relationships. Previous research has demonstrated the efficacy of CBCT in improving PTSD symptoms, partner functioning, and relationship satisfaction in both distressed and non-distressed dyads.
MDMA is a drug commonly used recreationally that has been increasingly studied because of its ability to reduce the impact of PTSD symptoms. The effects of MDMA are reduced fear, enhanced communication, trust and introspection, and increased empathy and compassion. The effects of MDMA create a state that enhances the positive effects of therapy by increasing the ability to tolerate negative emotions and allowing clients to stay engaged in therapy without being overwhelmed by the intense emotions surrounding the memories of traumatic events. It is believed that MDMA may help promote the effects of CBCT due to its ability to induce empathy and interpersonal openness.
This randomized study is the second study designed to explore the efficacy of combining MDMA-assisted therapy with CBCT. This study will enroll 30 dyads, where one individual has symptoms of PTSD. Participants will undergo a 7-week psychotherapy course, in MDMA-assisted CBCT or CBCT alone. In the MDMA-assisted CBCT, participants will go through CBCT sessions, and two doses of MDMA will be used as an adjunct to psychotherapy. Participants assigned to the CBCT-only condition will go through CBCT sessions and will have the opportunity to crossover and receive the two MDMA sessions after follow-up. The primary goal of this research is to contribute to the literature on MDMA-assisted CBCT by investigating its feasibility, safety, acceptability, and effectiveness, and by comparing it to active PTSD treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant with PTSD
Close Significant Other
Exclusion Criteria
Participant with PTSD
Close Significant Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
Drug: MDMA assisted psychotherapy
Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD. Dyads who have undergone the CBCT-Only condition will have the option to do a crossover and have the two MDMA sessions after follow-up.
Behavioral: Psychotherapy
This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
Also known as: MDMA-assisted CBCT
A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
Also known as: CBCT
Feasibility of Intervention Measure (FIM)
The Feasibility of Intervention Measure (FIM) is a self-report questionnaire in which respondents indicate the extent to which they believe that the treatment can be delivered in a given setting. Respondents indicate their responses on a five-point Likert-type (1=completely disagree, 5= completely agree).
Time frame: 3-Month Follow-up
Safety of Intervention
Safety will be assessed by examining the frequency and severity of adverse events (AEs), serious AEs (SAEs), treatment emergent AES (TEAEs), and AEs of special interest. Participants are asked to report any AEs, SAEs, TEAEs, and AEs of special interest as they happen and during any communication with the therapist or independent assessor.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Intervention Appropriateness Measures (IAM)
Intervention Appropriateness Measures (IAM) is a self-report measure of the perceived fit, relevance, or compatibility of an intervention. Respondents record their answers on a five-point Likert-type scale (1=completely disagree, 5= completely agree).
Time frame: 3-month follow-up
Long Term Follow-Up Questionnaire (LTFUQ)
The Long Term Follow-Up Questionnaire (LTFUQ) is a self-report measure that assesses the long-term benefits and harms of MDMA-assisted therapy.
Time frame: 3-Month Follow-up
Clinician Administered PTSD Scale (CAPS-5)
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Posttraumatic Stress Disorder Checklist for the DSM-5 (PCL-5)
PTSD Checklist for the DSM-5 (PCL-5) is a self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD. Participants indicate how much distress they have experienced due to symptoms on a five-point Likert-type scale (1 = not at all, 5 = extremely). The total PCL-5 score (a sum of all 20 items) provides an index of overall PTSD symptom severity with higher scores indicating higher severity.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Quality of Relationships Inventory (QRI)
The Quality of Relationships Inventory (QRI) is a self-report questionnaire that uses the role of situational, intrapersonal, and interpersonal in social support processes to assess supportive and conflictual aspects of close non-intimate relationships.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Couple Satisfaction Index (CSI)
The Couple Satisfaction Index (CSI) is a self-report questionnaire that measures intimate relationship functioning. Respondents answer most of the questions on a six-point Likert-type scale (0= never, 5= all the time) and one question on a seven-point Likert-type scale ( 0= extremely unhappy, 6= perfect).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 (PHQ-9) is used to assess depressive symptom severity. The PHQ-9 includes items which correspond with the diagnostic criteria for DSM-IV major depressive disorder. Scores can indicate either no depression, minimal, mild, moderate, moderately severe, or severe depression. Higher scores indicate higher severity in depressive symptoms.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Posttraumatic Growth Inventory (PTGI)
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life.
Time frame: Baseline (enrolment) to Follow-up (3 month follow-up)
Self-Compassion Scale-Short Form (SCS-SF)
The Self-Compassion Scale-Short Form (SCS-SF) is a 12-item self-report measures that assess self-compassion. This measure is comprised of the following subscales: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Respondents answer questions on a five-point Likert-type scale (1= almost never, 5= almost always).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Brief Experiential Avoidance Questionnaire (BEAQ)
The Brief Experiential Avoidance Questionnaire (BEAQ) is a 15-item self-report measure that assesses experiential avoidance. Respondents rate the extent to which they agree with each item on a six-point Likert-type scale (1 = strongly disagree, 6= strongly agree).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Alcohol Use Disorders Identification Test (AUDIT), Cannabis Use Disorders Identification Test-Revised (CUDIT-R), and Drug Use Disorders Identification Test (DUDIT)
The Alcohol Use Disorders Identification Test (AUDIT), Cannabis Use Disorders Identification Test-Revised (CUDIT-R), and Drug Use Disorders Identification Test (DUDIT) are self-report questionnaires that assess alcohol and substance use.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Brief Posttraumatic Cognitions Inventory (PTCI-9)
The Brief Posttraumatic Cognitions Inventory (PTCI-9) is a nine-item self-report questionnaire that measures appraisals related to trauma. Respondents answer the questionnaire on a seven-point Likert-type scale (1= totally disagree, 7= totally agree).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
MOS Social Support Survey (MOS-SSS)
The MOS Social Support Survey (MOS-SSS) is a 20-item multidimensional self-report questionnaire that assess perceived availability of social support. Respondents answer questions on a seven-point Likert-type scale (1 = none of the time, 7= all of the time), where higher score indicate greater levels of available social support.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Significant Others' Responses to Trauma Scale (SORTS)
The Significant Others' Responses to Trauma Scale (SORTS) is a 14-item self-report questionnaire that measures relationship problems and the psychological distress of partners of people with PTSD. Respondents answer questions on a five-point Likert scale (0-4).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Modified Experiences in Close Relationships (ECR-M16)
The Modified Experiences in Close Relationships (ECR-M16) is a 16-item self-report questionnaire that assesses attachment style. Half of the items on the scale measure attachment anxiety and the other half measures attachment avoidance. Respondents answer questions on a seven-point Likert-type scale (1= disagree, 7=agree).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Psychological Insights Questionnaire (PIQ)
The Psychological Insights Questionnaire (PIQ) is a a 23-item self-report measure that assesses acute experiences of insight (i.e., beliefs, memories, emotions, etc.). Respondents answer questions on a six-point Likert-type scale (0= no, not at all; 5= extremely).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Mystical Experiences Questionnaire (MEQ30)
The Mystical Experiences Questionnaire (MEQ30) is a 30-item self-report questionnaire that assesses discrete mystical experiences. Respondents rate the extent to which the experience mystical feeling, positive mood, transcendence of space/time, and ineffability on a five-point Likert-type scale (0= no/not at all, 4= extreme).
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Columbia-Suicide Severity Rating Scale (C-SSRS)
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-administered measure of suicidal behaviour devised to detect potential suicidal thoughts or behaviours. It is designed to assess suicidal ideation, ideation intensity, and behaviour.
Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)
Credibility Expectancy Questionnaire (CEQ)
The Credibility Expectancy Questionnaire (CEQ) is a six-item self-report measure of beliefs about treatment credibility and expectancy of treatment outcomes. The some questions on the questionnaire are answered on a scale ranging from 1 (not at all) to 9 (very much) and that others are answered on a scale ranging from 0 (not at all) to 100% (very much).
Time frame: Baseline (enrolment)
Working Alliance Inventory-Observer Form (WAI-O)
The Working Alliance Inventory-Observer Form (WAI-O) is a 36-item observer-rated measure of the alliance between a therapist and client. Observers rate each item on a scale from 1 (Never applies to the dyad) to 7 (Always applies to the dyad).
Time frame: First therapy session, Mid-point, and Follow-up (3-month follow-up)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's planned 28 months is above that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →